COTELLIC (cobimetinib)

ORAL ADMINISTRATION

Indications for Prior Authorization:

  • Melanoma: Indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib
  • Histiocytic Neoplasms: indicated for the treatment of adult patients with histiocytic neoplasms.

 

Coverage Criteria:

 

For diagnosis of melanoma:

  • Patient has unresectable or metastatic melanoma; AND
  • One of the following (A or B):
    • A) Patient has a BRAF V600E mutation as detected by a U.S. Food and Drug Administration (FDA)-approved test (e.g., cobas 4800 BRAF V600 Mutation Test) or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA), or 
    • B) Patient has a BRAF V600K mutation as detected by a U.S. Food and Drug Administration (FDA)-approved test (e.g., cobas 4800 BRAF V600 Mutation Test) or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA), AND
  • Used in combination with Zelboraf (vemurafenib) *

*This product may require a prior authorization

 

For diagnosis of histiocytic neoplasms:

  • Patient has histiocytic neoplasm; AND
  • Used as monotherapy

 

Reauthorization Criteria:

For diagnosis all indications:

  • Patient has not experienced disease progression while on therapy 

 

Coverage Duration: 

For diagnosis of melanoma melanoma or histiocytic neoplasms:

  • Initial: 12 months

  • Reauthorization: 12 months 

 

Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

 

Policy Updates:
  • 7/25/2016 - Initial review
  • 3/1/2024 (policy effective date)- Updated criteria for melanoma.  Created criteria for histiocytic neoplasms. (P&T 2/20/2024) (P&T meeting February)

 
 

References:
  • Cotellic Prescribing Information. Genentech, Inc. South San Francisco, CA. October 2022. 
  • Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-76. 
  • U.S. Food and Drug Administration. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm. Accessed May 30, 2023. 
     

 

Last review date: March 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone